Figure 4
From: Cytoplasmic HIF-2α as tissue biomarker to identify metastatic sympathetic paraganglioma
Intense staining of cytoplasmic HIF-2α predicts poor outcome in sPGLs. (A) Survival probability (10-year follow-up) of PPGL patients when including all causes of death. (B) Survival probability (10-year follow-up) of patients when only including patients dead from PPGL disease comparing PCC and PGL subgroups. (C)–(D) Survival probability (10-year follow-up) of PPGL patients divided into PGL and PCC subgroups when including all causes of death (C) and only PPGL caused deaths (D). (E)–(F) Survival probability stratified by low (0–1) and high (2–3) staining intensity of cytoplasmic HIF-2α in the entire PPGL cohort (E) and PCC (F). (G)–(H) Survival probability (10-year follow-up) of patients when only including patients dead from PPGL disease in PGL (G) and sPGL (H) comparing low (0–1) and high (2–3) staining intensity of cytoplasmic HIF-2α. Statistical significance was calculated using the Log-rank (Mantel–Cox) test. PCC pheochromocytoma, sPGL sympathetic paraganglioma, HN-PGL head- and neck paraganglioma, PGL paraganglioma, PPGL pheochromocytoma and paraganglioma.
